AdvisorShares Issues Statement on Finalization of Federal Cannabis Rescheduling
Rhea-AI Summary
AdvisorShares (MSOS) responded to the Department of Justice's April 23, 2026 final reclassification of cannabis to Schedule III under the Controlled Substances Act. AdvisorShares called rescheduling an industry inflection point, citing potential access to research, capital, relief from punitive tax treatment, and increased institutional participation. The firm noted the industry employs over 400,000 Americans and highlighted its MSOS, YOLO, and MSOX ETFs managed by Dan Ahrens.
Positive
- Federal rescheduling to Schedule III
- U.S. cannabis industry employs more than 400,000 Americans
- MSOS identified as the largest U.S.-listed cannabis ETF
Negative
- AdvisorShares states rescheduling does not instantly solve every challenge
- Cannabis-related investments remain subject to regulatory, taxation, and licensing risks
Key Figures
Market Reality Check
Peers on Argus
No peers with momentum or same-day headlines were provided, so the +19.39% move in MSOS appears stock-specific in the context of this data.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Federal policy statement | Positive | -0.2% | AdvisorShares response to Executive Order advancing federal cannabis rescheduling efforts. |
Limited history shows one prior federal cannabis policy statement that was positive in tone but followed by a slight negative price reaction, suggesting past divergence between narrative and price.
On Dec 18, 2025, AdvisorShares issued a statement on a Presidential Executive Order to advance cannabis reclassification, highlighting potential impacts on taxation, research access, and capital formation for U.S. cannabis companies and more than 400,000 workers. MSOS, described as the largest U.S. cannabis ETF, saw a -0.2% 24-hour reaction, a mild divergence from the constructive policy tone. Today’s news marks the Department of Justice’s final action to reclassify cannabis to Schedule III, advancing the same policy trajectory.
Market Pulse Summary
This announcement framed the Department of Justice’s move to reclassify cannabis to Schedule III as a structural shift for U.S. operators, potentially affecting tax treatment, research access, and capital formation. MSOS was already trading above its 200-day MA of 4.19 and well off its 52-week low of 2.06 prior to publication. Investors tracking this theme may focus on how future banking access, licensing stability, and federal–state alignment evolve from this new baseline.
Key Terms
exchange-traded funds financial
etf financial
schedule iii regulatory
controlled substances act regulatory
leveraged etf financial
prospectus regulatory
AI-generated analysis. Not financial advice.
MSOS portfolio manager calls action an inflection point for the
"This is the moment the
Ahrens continued, "This action does not instantly solve every challenge facing the industry, but it removes one of the most significant structural barriers. By enabling relief from punitive tax treatment and expanding access to research, capital, and institutional participation, rescheduling represents the true starting point for cannabis to function as a normalized
The reclassification marks a critical transition for an industry that employs more than 400,000 Americans and operates across a majority of
The AdvisorShares Pure US Cannabis ETF (Ticker: MSOS) is an actively managed ETF focused primarily on
AdvisorShares also offers the AdvisorShares Pure Cannabis ETF (Ticker: YOLO), an actively managed global cannabis strategy, and the AdvisorShares MSOS Daily Leveraged ETF (Ticker: MSOX), which provides leveraged exposure to the
"From an investment perspective, rescheduling is not the end of the story—it is the beginning," Ahrens added. "It establishes the conditions under which fundamentals, not federal uncertainty, can begin to drive valuations."
For more information, please visit www.advisorshares.com.
About AdvisorShares
AdvisorShares is a leading provider of actively managed ETFs, delivering differentiated investment solutions across equities, alternatives and thematic strategies. Financial professionals and investors seeking more information may call 1-877-843-3831 or visit advisorshares.com.
Each weekday at 12:00 pm ET, AdvisorShares hosts the live AlphaNooner webcast, featuring timely discussions on markets, portfolio construction, and emerging investment themes, including cannabis. Viewers can watch and engage live via X, LinkedIn, Facebook and YouTube.
Before investing you should carefully consider the Fund's investment objectives, risks, charges and expenses. This and other information is in the prospectus, which may be obtained by visiting the Fund's website at www.AdvisorShares.com. Please read the prospectus and summary prospectus carefully before investing. Foreside Fund Services, LLC, distributor.
An investment in the Funds is subject to risk, including the possible loss of principal. Cannabis-related investments are subject to additional risks, including regulatory risk, market volatility, and risks related to taxation, licensing, and changing federal and state laws. Shares are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Additional risk information is available in each Fund's prospectus.
Cannabis-Related Company Risk – Cannabis-related companies are subject to various laws and regulations that may differ at the state/local and federal level. These laws and regulations may (i) significantly affect a cannabis-related company's ability to secure financing, (ii) impact the market for marijuana industry sales and services, and (iii) set limitations on marijuana use, production, transportation, and storage. Cannabis-related companies may also be required to secure permits and authorizations from government agencies to cultivate or research marijuana. In addition, cannabis-related companies are subject to the risks associated with the greater agricultural industry, including changes to or trends that affect commodity prices, labor costs, weather conditions, and laws and regulations related to environmental protection, health and safety. Cannabis-related companies may also be subject to risks associated with the biotechnology and pharmaceutical industries. These risks include increased government regulation, the use and enforcement of intellectual property rights and patents, technological change and obsolescence, product liability lawsuits, and the risk that research and development may not necessarily lead to commercially successful products.
View original content to download multimedia:https://www.prnewswire.com/news-releases/advisorshares-issues-statement-on-finalization-of-federal-cannabis-rescheduling-302751859.html
SOURCE AdvisorShares